Arthropod-borne Viral Infections Testing Market by Test Type (Antibody Testing, Antigen Testing, Molecular Testing), Technology (Immunoassay, Next Generation Sequencing, PCR Based Technologies), Sample Type, Disease Type, End User - Global Forecast 2025-2
Description
The Arthropod-borne Viral Infections Testing Market was valued at USD 11.66 billion in 2024 and is projected to grow to USD 12.66 billion in 2025, with a CAGR of 8.79%, reaching USD 22.88 billion by 2032.
A strategic introduction to the current diagnostic ecosystem for arthropod-borne viral infections emphasizing clinical, laboratory, and public health imperatives
Arthropod-borne viral infections present a complex diagnostic landscape driven by episodic outbreaks, overlapping clinical syndromes, and evolving laboratory capabilities. Accurate detection is critical not only for individual patient management but also for public health surveillance, vector control strategies, and global disease reporting systems. Diagnostic testing spans serological, antigen, and molecular modalities, each bringing distinct sensitivity, specificity, turnaround time, and operational requirements. Clinicians and laboratory directors must balance these trade-offs while contending with seasonality and geographic variability in pathogen prevalence.
Recent years have seen intensified investments in rapid diagnostics, multiplexed assays, and genomic surveillance as stakeholders seek to close gaps in early detection and outbreak response. Meanwhile, the interplay between reagent supply chains, regulatory pathways, and payer considerations continues to influence adoption timelines in both clinical and reference laboratory settings. As such, an integrated view of technology performance, end-user needs, and regulatory environments is essential for decision-makers planning diagnostic portfolios, procurement strategies, and capacity-building initiatives. This executive summary synthesizes the most consequential trends, segmentation insights, regional differentials, and practical recommendations relevant to laboratory leaders, policymakers, and commercial stakeholders.
How converging innovations in molecular, serological, and sequencing technologies are reshaping diagnostic pathways and stakeholder expectations across health systems
The testing landscape for arthropod-borne viral infections is undergoing transformative shifts driven by converging technological maturation, shifting clinical priorities, and enhanced public health investment. Molecular diagnostics have moved from centralized reference labs toward decentralized and rapid platforms, enabling faster confirmation of acute infections and supporting outbreak containment efforts. Concurrently, serological assays are evolving to provide more precise differentiation between recent and past infections, which is crucial for diseases with cross-reactivity challenges and overlapping symptomatology.
Next-generation sequencing and genomic surveillance have transitioned from research-only applications to operational tools that inform lineage tracking, vector dynamics, and vaccine or therapeutic design. Rapid diagnostic tests have improved in analytical performance and user experience, increasing their utility in field settings and resource-constrained environments. These technological advances are paralleled by changes in procurement behavior: institutions increasingly value integrated solutions that combine robust analytics, supply security, and regulatory compliance. As a result, vendors and laboratories are adapting business models to prioritize resilience, interoperability, and data-driven decision support, thereby reshaping competitive dynamics and clinical pathways.
Evaluating the downstream effects of 2025 tariff changes on reagent costs, equipment procurement patterns, and supply chain resilience for diagnostic stakeholders
Tariff policy changes in the United States in 2025 have exerted a multifaceted influence on the diagnostics supply chain, affecting reagent availability, equipment costs, and procurement strategies. Increased import duties on certain laboratory instruments and reagent components have raised landed costs for many diagnostic manufacturers and end users, prompting laboratories to reassess supplier portfolios and inventory management practices. In response, some manufacturers have accelerated localization of critical component production, while others have reevaluated pricing structures and contractual terms to preserve access for diagnostic laboratories.
These tariff-driven dynamics have also influenced the cadence of capital equipment purchases and instrument placements. Health systems and diagnostic centers weighed immediacy of needs against higher acquisition costs, often opting for phased rollouts or extended leasing arrangements. For smaller research and academic institutions, the increased cost burden stressed operating budgets and amplified the need for grant support or collaborative purchasing arrangements. Moreover, tariffs contributed to faster diversification of supply chains, with procurement teams seeking alternative manufacturers in tariff-exempt jurisdictions or investing in longer-term relationships with regional distributors to reduce exposure to future policy volatility. Overall, the cumulative impact of tariff adjustments has been to heighten the emphasis on supply chain resilience, supplier transparency, and total cost of ownership in diagnostic decision-making.
Comprehensive segmentation analysis linking test modalities, technology platforms, end-user priorities, sample matrices, and disease-specific diagnostic requirements
Segmentation-driven insights reveal differentiated demand drivers and adoption curves across test types, technologies, end users, sample types, and disease indications. Within test type segmentation, antibody testing continues to play a central role for retrospective exposure assessment and population serosurveys, with distinct clinical utility between IgG antibody detection for past infection and IgM antibody detection for more recent seroconversion. Antigen testing serves as a bridge for rapid case identification and triage; enzyme-linked immunosorbent antigens remain valuable in laboratory workflows, while rapid antigen formats enable point-of-care screening in ambulatory and field settings. Molecular testing remains the cornerstone for definitive diagnosis, with conventional PCR retaining importance in established labs, isothermal amplification gaining traction for simplified workflows, and real-time PCR offering both quantitative capability and broad clinical acceptance.
When viewed through the technology lens, immunoassays, next-generation sequencing, PCR-based platforms, and rapid diagnostic tests present divergent value propositions. Immunoassays span chemiluminescent techniques for high-throughput lab environments, ELISA for established serology workflows, and lateral flow immunoassays for decentralized testing. Next-generation sequencing supports granular pathogen characterization with platforms such as short-read sequencers increasingly incorporated into surveillance initiatives. PCR-based technologies marry sensitivity with familiarity, while rapid diagnostic tests prioritize speed and usability. End-user segmentation indicates that academic institutions and research institutes prioritize analytical depth and methodological flexibility, whereas diagnostic centers, hospital laboratories, and reference laboratories emphasize throughput, turnaround time, and integration with clinical information systems. Sample type considerations-ranging from blood serum and plasma to whole blood, cerebrospinal fluid, and saliva-drive assay design, pre-analytical requirements, and deployment scenarios. Finally, disease-type segmentation across chikungunya, dengue, West Nile, yellow fever, and Zika emphasizes differing clinical presentations, cross-reactivity challenges, and surveillance priorities that shape testing algorithms and product development focus.
Regional diagnostic landscape overview highlighting how geographic variations in policy, capacity, and procurement shape testing adoption across the globe
Regional dynamics exert a powerful influence on diagnostic priorities, regulatory pathways, and adoption timelines across the Americas, Europe Middle East & Africa, and Asia-Pacific markets. In the Americas, public health infrastructure and established private laboratory networks create demand for both high-throughput centralized testing and rapid decentralized solutions for outbreak hotspots. Regulatory clarity and reimbursement frameworks in parts of North and South America facilitate quicker commercialization cycles for validated assays, yet disparities in resource allocation can lead to heterogeneous access in rural or underserved areas.
Across Europe, the Middle East, and Africa, regulatory convergence in some subregions coexists with localized approval nuances and logistical constraints. This region exhibits strong interest in scalable surveillance tools and cost-effective rapid diagnostics suited for variable health system capacities. In the Asia-Pacific context, diverse economic profiles drive a dual market structure: advanced economies pursue next-generation sequencing and integrated laboratory information systems, while emerging markets prioritize affordable, robust rapid diagnostic tests and point-of-care platforms. Cross-border collaboration, regional procurement mechanisms, and targeted capacity-building initiatives are increasingly shaping how testing solutions are selected and deployed throughout these geographies.
Key competitive levers driving differentiation among diagnostic providers including portfolio strategy, regulatory validation, supply chain robustness, and integrated service models
Competitive dynamics in the arthropod-borne viral infections testing space center on product portfolio breadth, regulatory credentials, manufacturing scalability, and integrated service offerings. Leading firms and innovators focus on differentiating through analytical performance, time-to-result improvements, and multiplexing capabilities that address clinical overlap among arboviral diseases. Strategic investments in quality management systems, ISO compliance, and clinical validation studies strengthen market credibility and accelerate adoption among cautious laboratory directors. Partnerships between diagnostic companies and research institutions have also become a critical route for co-developing assays that are clinically validated in endemic settings and that incorporate local epidemiological nuance.
Manufacturers with vertically integrated supply chains and regional manufacturing footprints have an advantage in mitigating tariff- and logistics-related disruptions. Meanwhile, nimble start-ups concentrate on niche opportunities such as simplified isothermal platforms, portable sequencing workflows, and novel sample-to-answer rapid tests optimized for field deployment. Service-oriented models that bundle assay kits with training, remote technical support, and data analytics are gaining traction, particularly among hospital laboratories and reference centers seeking turnkey implementations. Competitive positioning increasingly rests on proving consistent reagent supply, demonstrating real-world performance across diverse sample types, and offering flexible commercial terms that accommodate institutional procurement cycles.
Actionable strategic steps for manufacturers and laboratory leaders to bolster supply resilience, validation rigor, interoperability, and scalable deployment of diagnostics
Industry leaders should prioritize a set of pragmatic actions to strengthen diagnostic readiness, ensure continuity of supply, and accelerate responsible adoption of new technologies. First, invest in diversified supply chains and regional manufacturing partnerships to reduce exposure to policy-induced cost fluctuations and to shorten lead times for critical reagents and consumables. Second, expand clinical validation programs to include diverse sample types and disease contexts, thereby reducing uncertainty around cross-reactivity and improving clinician confidence in test interpretation. Third, pursue interoperability with laboratory information systems and public health reporting platforms to enhance the utility of diagnostic data for surveillance and operational decision-making.
Additionally, manufacturers and laboratories should co-design deployment models that align technical performance with end-user workflow realities-this includes tailored training packages, quality control protocols, and scalable maintenance programs. Consider adopting demand-flexible commercial terms such as consignment inventory, reagent rental, or modular instrument upgrades to lower barriers for adoption in resource-constrained settings. Finally, invest in transparent communication about assay limitations, intended use cases, and performance in endemic versus non-endemic populations to support informed clinical use and to build long-term trust with public health stakeholders.
Transparent and rigorous research methodology blending primary stakeholder interviews, technical validation review, and secondary evidence synthesis with clear limitations and validation
The research underpinning this report combined primary stakeholder engagement with systematic secondary evidence gathering to ensure robust, reproducible insights. Primary research included structured interviews with clinical laboratory directors, procurement officers, assay developers, and public health practitioners to capture operational pain points, procurement drivers, and real-world performance expectations. These conversations were complemented by protocol reviews of assay validation studies, regulatory clearance documentation, and technical whitepapers to triangulate claims about sensitivity, specificity, and operational suitability across use cases.
Secondary research encompassed peer-reviewed literature, clinical guidelines, technical standards, and public health agency reports to provide contextual grounding for epidemiological trends and diagnostic best practices. Data synthesis employed cross-validation techniques to identify consistent themes and to surface areas of uncertainty. Limitations were acknowledged and addressed through sensitivity analyses, with methodological transparency maintained regarding interview sampling frames, inclusion criteria for technical studies, and the scope of device types reviewed. This multi-pronged approach balances depth and breadth, yielding findings that are actionable for decision-makers while clearly delineating areas where further empirical study would strengthen confidence.
Concluding synthesis of diagnostic priorities emphasizing validation, supply chain resilience, interoperability, and collaborative approaches for sustained impact
In conclusion, the diagnostic landscape for arthropod-borne viral infections is at an inflection point characterized by technological maturation, heightened emphasis on supply chain resilience, and growing expectations for integrated data-driven solutions. Molecular platforms, improved serological assays, and portable rapid tests each contribute distinct value that must be aligned with clinical workflows, surveillance objectives, and resource realities. Regulatory clarity and robust clinical validation remain essential to translate promising technologies into routine practice, while procurement strategies that emphasize total cost of ownership and supplier reliability will determine which solutions achieve sustained uptake.
Looking forward, stakeholders who invest in interoperable systems, diversify supply relationships, and rigorously validate assays across matrix types and epidemiological contexts will be better positioned to respond to both routine diagnostic demand and episodic outbreak pressures. Collaborative approaches that pair technological innovation with capacity-building efforts and transparent performance communication will accelerate responsible adoption and deliver the most meaningful public health impact.
Note: PDF & Excel + Online Access - 1 Year
A strategic introduction to the current diagnostic ecosystem for arthropod-borne viral infections emphasizing clinical, laboratory, and public health imperatives
Arthropod-borne viral infections present a complex diagnostic landscape driven by episodic outbreaks, overlapping clinical syndromes, and evolving laboratory capabilities. Accurate detection is critical not only for individual patient management but also for public health surveillance, vector control strategies, and global disease reporting systems. Diagnostic testing spans serological, antigen, and molecular modalities, each bringing distinct sensitivity, specificity, turnaround time, and operational requirements. Clinicians and laboratory directors must balance these trade-offs while contending with seasonality and geographic variability in pathogen prevalence.
Recent years have seen intensified investments in rapid diagnostics, multiplexed assays, and genomic surveillance as stakeholders seek to close gaps in early detection and outbreak response. Meanwhile, the interplay between reagent supply chains, regulatory pathways, and payer considerations continues to influence adoption timelines in both clinical and reference laboratory settings. As such, an integrated view of technology performance, end-user needs, and regulatory environments is essential for decision-makers planning diagnostic portfolios, procurement strategies, and capacity-building initiatives. This executive summary synthesizes the most consequential trends, segmentation insights, regional differentials, and practical recommendations relevant to laboratory leaders, policymakers, and commercial stakeholders.
How converging innovations in molecular, serological, and sequencing technologies are reshaping diagnostic pathways and stakeholder expectations across health systems
The testing landscape for arthropod-borne viral infections is undergoing transformative shifts driven by converging technological maturation, shifting clinical priorities, and enhanced public health investment. Molecular diagnostics have moved from centralized reference labs toward decentralized and rapid platforms, enabling faster confirmation of acute infections and supporting outbreak containment efforts. Concurrently, serological assays are evolving to provide more precise differentiation between recent and past infections, which is crucial for diseases with cross-reactivity challenges and overlapping symptomatology.
Next-generation sequencing and genomic surveillance have transitioned from research-only applications to operational tools that inform lineage tracking, vector dynamics, and vaccine or therapeutic design. Rapid diagnostic tests have improved in analytical performance and user experience, increasing their utility in field settings and resource-constrained environments. These technological advances are paralleled by changes in procurement behavior: institutions increasingly value integrated solutions that combine robust analytics, supply security, and regulatory compliance. As a result, vendors and laboratories are adapting business models to prioritize resilience, interoperability, and data-driven decision support, thereby reshaping competitive dynamics and clinical pathways.
Evaluating the downstream effects of 2025 tariff changes on reagent costs, equipment procurement patterns, and supply chain resilience for diagnostic stakeholders
Tariff policy changes in the United States in 2025 have exerted a multifaceted influence on the diagnostics supply chain, affecting reagent availability, equipment costs, and procurement strategies. Increased import duties on certain laboratory instruments and reagent components have raised landed costs for many diagnostic manufacturers and end users, prompting laboratories to reassess supplier portfolios and inventory management practices. In response, some manufacturers have accelerated localization of critical component production, while others have reevaluated pricing structures and contractual terms to preserve access for diagnostic laboratories.
These tariff-driven dynamics have also influenced the cadence of capital equipment purchases and instrument placements. Health systems and diagnostic centers weighed immediacy of needs against higher acquisition costs, often opting for phased rollouts or extended leasing arrangements. For smaller research and academic institutions, the increased cost burden stressed operating budgets and amplified the need for grant support or collaborative purchasing arrangements. Moreover, tariffs contributed to faster diversification of supply chains, with procurement teams seeking alternative manufacturers in tariff-exempt jurisdictions or investing in longer-term relationships with regional distributors to reduce exposure to future policy volatility. Overall, the cumulative impact of tariff adjustments has been to heighten the emphasis on supply chain resilience, supplier transparency, and total cost of ownership in diagnostic decision-making.
Comprehensive segmentation analysis linking test modalities, technology platforms, end-user priorities, sample matrices, and disease-specific diagnostic requirements
Segmentation-driven insights reveal differentiated demand drivers and adoption curves across test types, technologies, end users, sample types, and disease indications. Within test type segmentation, antibody testing continues to play a central role for retrospective exposure assessment and population serosurveys, with distinct clinical utility between IgG antibody detection for past infection and IgM antibody detection for more recent seroconversion. Antigen testing serves as a bridge for rapid case identification and triage; enzyme-linked immunosorbent antigens remain valuable in laboratory workflows, while rapid antigen formats enable point-of-care screening in ambulatory and field settings. Molecular testing remains the cornerstone for definitive diagnosis, with conventional PCR retaining importance in established labs, isothermal amplification gaining traction for simplified workflows, and real-time PCR offering both quantitative capability and broad clinical acceptance.
When viewed through the technology lens, immunoassays, next-generation sequencing, PCR-based platforms, and rapid diagnostic tests present divergent value propositions. Immunoassays span chemiluminescent techniques for high-throughput lab environments, ELISA for established serology workflows, and lateral flow immunoassays for decentralized testing. Next-generation sequencing supports granular pathogen characterization with platforms such as short-read sequencers increasingly incorporated into surveillance initiatives. PCR-based technologies marry sensitivity with familiarity, while rapid diagnostic tests prioritize speed and usability. End-user segmentation indicates that academic institutions and research institutes prioritize analytical depth and methodological flexibility, whereas diagnostic centers, hospital laboratories, and reference laboratories emphasize throughput, turnaround time, and integration with clinical information systems. Sample type considerations-ranging from blood serum and plasma to whole blood, cerebrospinal fluid, and saliva-drive assay design, pre-analytical requirements, and deployment scenarios. Finally, disease-type segmentation across chikungunya, dengue, West Nile, yellow fever, and Zika emphasizes differing clinical presentations, cross-reactivity challenges, and surveillance priorities that shape testing algorithms and product development focus.
Regional diagnostic landscape overview highlighting how geographic variations in policy, capacity, and procurement shape testing adoption across the globe
Regional dynamics exert a powerful influence on diagnostic priorities, regulatory pathways, and adoption timelines across the Americas, Europe Middle East & Africa, and Asia-Pacific markets. In the Americas, public health infrastructure and established private laboratory networks create demand for both high-throughput centralized testing and rapid decentralized solutions for outbreak hotspots. Regulatory clarity and reimbursement frameworks in parts of North and South America facilitate quicker commercialization cycles for validated assays, yet disparities in resource allocation can lead to heterogeneous access in rural or underserved areas.
Across Europe, the Middle East, and Africa, regulatory convergence in some subregions coexists with localized approval nuances and logistical constraints. This region exhibits strong interest in scalable surveillance tools and cost-effective rapid diagnostics suited for variable health system capacities. In the Asia-Pacific context, diverse economic profiles drive a dual market structure: advanced economies pursue next-generation sequencing and integrated laboratory information systems, while emerging markets prioritize affordable, robust rapid diagnostic tests and point-of-care platforms. Cross-border collaboration, regional procurement mechanisms, and targeted capacity-building initiatives are increasingly shaping how testing solutions are selected and deployed throughout these geographies.
Key competitive levers driving differentiation among diagnostic providers including portfolio strategy, regulatory validation, supply chain robustness, and integrated service models
Competitive dynamics in the arthropod-borne viral infections testing space center on product portfolio breadth, regulatory credentials, manufacturing scalability, and integrated service offerings. Leading firms and innovators focus on differentiating through analytical performance, time-to-result improvements, and multiplexing capabilities that address clinical overlap among arboviral diseases. Strategic investments in quality management systems, ISO compliance, and clinical validation studies strengthen market credibility and accelerate adoption among cautious laboratory directors. Partnerships between diagnostic companies and research institutions have also become a critical route for co-developing assays that are clinically validated in endemic settings and that incorporate local epidemiological nuance.
Manufacturers with vertically integrated supply chains and regional manufacturing footprints have an advantage in mitigating tariff- and logistics-related disruptions. Meanwhile, nimble start-ups concentrate on niche opportunities such as simplified isothermal platforms, portable sequencing workflows, and novel sample-to-answer rapid tests optimized for field deployment. Service-oriented models that bundle assay kits with training, remote technical support, and data analytics are gaining traction, particularly among hospital laboratories and reference centers seeking turnkey implementations. Competitive positioning increasingly rests on proving consistent reagent supply, demonstrating real-world performance across diverse sample types, and offering flexible commercial terms that accommodate institutional procurement cycles.
Actionable strategic steps for manufacturers and laboratory leaders to bolster supply resilience, validation rigor, interoperability, and scalable deployment of diagnostics
Industry leaders should prioritize a set of pragmatic actions to strengthen diagnostic readiness, ensure continuity of supply, and accelerate responsible adoption of new technologies. First, invest in diversified supply chains and regional manufacturing partnerships to reduce exposure to policy-induced cost fluctuations and to shorten lead times for critical reagents and consumables. Second, expand clinical validation programs to include diverse sample types and disease contexts, thereby reducing uncertainty around cross-reactivity and improving clinician confidence in test interpretation. Third, pursue interoperability with laboratory information systems and public health reporting platforms to enhance the utility of diagnostic data for surveillance and operational decision-making.
Additionally, manufacturers and laboratories should co-design deployment models that align technical performance with end-user workflow realities-this includes tailored training packages, quality control protocols, and scalable maintenance programs. Consider adopting demand-flexible commercial terms such as consignment inventory, reagent rental, or modular instrument upgrades to lower barriers for adoption in resource-constrained settings. Finally, invest in transparent communication about assay limitations, intended use cases, and performance in endemic versus non-endemic populations to support informed clinical use and to build long-term trust with public health stakeholders.
Transparent and rigorous research methodology blending primary stakeholder interviews, technical validation review, and secondary evidence synthesis with clear limitations and validation
The research underpinning this report combined primary stakeholder engagement with systematic secondary evidence gathering to ensure robust, reproducible insights. Primary research included structured interviews with clinical laboratory directors, procurement officers, assay developers, and public health practitioners to capture operational pain points, procurement drivers, and real-world performance expectations. These conversations were complemented by protocol reviews of assay validation studies, regulatory clearance documentation, and technical whitepapers to triangulate claims about sensitivity, specificity, and operational suitability across use cases.
Secondary research encompassed peer-reviewed literature, clinical guidelines, technical standards, and public health agency reports to provide contextual grounding for epidemiological trends and diagnostic best practices. Data synthesis employed cross-validation techniques to identify consistent themes and to surface areas of uncertainty. Limitations were acknowledged and addressed through sensitivity analyses, with methodological transparency maintained regarding interview sampling frames, inclusion criteria for technical studies, and the scope of device types reviewed. This multi-pronged approach balances depth and breadth, yielding findings that are actionable for decision-makers while clearly delineating areas where further empirical study would strengthen confidence.
Concluding synthesis of diagnostic priorities emphasizing validation, supply chain resilience, interoperability, and collaborative approaches for sustained impact
In conclusion, the diagnostic landscape for arthropod-borne viral infections is at an inflection point characterized by technological maturation, heightened emphasis on supply chain resilience, and growing expectations for integrated data-driven solutions. Molecular platforms, improved serological assays, and portable rapid tests each contribute distinct value that must be aligned with clinical workflows, surveillance objectives, and resource realities. Regulatory clarity and robust clinical validation remain essential to translate promising technologies into routine practice, while procurement strategies that emphasize total cost of ownership and supplier reliability will determine which solutions achieve sustained uptake.
Looking forward, stakeholders who invest in interoperable systems, diversify supply relationships, and rigorously validate assays across matrix types and epidemiological contexts will be better positioned to respond to both routine diagnostic demand and episodic outbreak pressures. Collaborative approaches that pair technological innovation with capacity-building efforts and transparent performance communication will accelerate responsible adoption and deliver the most meaningful public health impact.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of multiplex PCR panels enabling simultaneous detection of dengue chikungunya and Zika viruses
- 5.2. Adoption of portable point-of-care diagnostic devices with CRISPR-based arboviral detection technology
- 5.3. Expansion of at-home test kits for mosquito-borne virus screening with smartphone connectivity
- 5.4. Implementation of AI-driven predictive analytics platforms for real-time outbreak surveillance and testing prioritization
- 5.5. Development of next-generation serological assays differentiating cross-reactive flavivirus antibodies in endemic regions
- 5.6. Partnerships between diagnostic companies and global health organizations for scalable arboviral testing in resource-limited settings
- 5.7. Regulatory approvals accelerating commercialization of high-throughput automated platforms for large-scale arbovirus screening
- 5.8. Research advances in nanopore sequencing for direct RNA identification of emerging mosquito-borne viruses in field settings
- 5.9. Increased government funding for establishing sentinel testing networks and genomic surveillance of arthropod-borne viruses
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Arthropod-borne Viral Infections Testing Market, by Test Type
- 8.1. Antibody Testing
- 8.1.1. IgG Antibody
- 8.1.2. IgM Antibody
- 8.2. Antigen Testing
- 8.2.1. Elisa Antigen
- 8.2.2. Rapid Antigen
- 8.3. Molecular Testing
- 8.3.1. Conventional PCR
- 8.3.2. Isothermal Amplification
- 8.3.3. Real Time PCR
- 9. Arthropod-borne Viral Infections Testing Market, by Technology
- 9.1. Immunoassay
- 9.1.1. Chemiluminescent Immunoassay
- 9.1.2. Elisa
- 9.1.3. Lateral Flow Immunoassay
- 9.2. Next Generation Sequencing
- 9.2.1. Illumina Sequencing
- 9.2.2. Pyrosequencing
- 9.3. PCR Based Technologies
- 9.3.1. Conventional PCR
- 9.3.2. Isothermal Amplification
- 9.3.3. Real Time PCR
- 9.4. Rapid Diagnostic Test
- 9.4.1. Lateral Flow Assay
- 9.4.2. Optical Immunoassay
- 10. Arthropod-borne Viral Infections Testing Market, by Sample Type
- 10.1. Blood Serum
- 10.2. Cerebrospinal Fluid
- 10.3. Plasma
- 10.4. Saliva
- 10.5. Whole Blood
- 11. Arthropod-borne Viral Infections Testing Market, by Disease Type
- 11.1. Chikungunya
- 11.2. Dengue
- 11.3. West Nile
- 11.4. Yellow Fever
- 11.5. Zika
- 12. Arthropod-borne Viral Infections Testing Market, by End User
- 12.1. Academic Institutions
- 12.2. Diagnostic Centers
- 12.3. Hospital Laboratories
- 12.4. Reference Laboratories
- 12.5. Research Institutes
- 13. Arthropod-borne Viral Infections Testing Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Arthropod-borne Viral Infections Testing Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Arthropod-borne Viral Infections Testing Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. F. Hoffmann-La Roche Ltd.
- 16.3.2. Abbott Laboratories
- 16.3.3. Thermo Fisher Scientific Inc.
- 16.3.4. bioMérieux SA
- 16.3.5. DiaSorin S.p.A.
- 16.3.6. Bio-Rad Laboratories, Inc.
- 16.3.7. Abnova Corporation
- 16.3.8. AdvaCare Pharma
- 16.3.9. Chembio Diagnostics, Inc.
- 16.3.10. EUROIMMUN AG by PerkinElmer Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
